NATIONAL KIDNEY FOUNDATION®

IgAN Medication Table: A Guide for Healthcare Professionals

Brand name (Generic)	Approval Date* (for IgAN)	Target/ Mechanism**	Dosing & Administration	REMS Program	Adverse Reactions Seen in Clinical Trials	Patient Support Program
Tarpeyo (targeted-release budesonide)	Dec 2021 (Accelerated) Dec 2023 (Full)	**Hits 1-3:** Targeted-release corticosteroid acting on mucosal B-cells to reduce production of pathogenic IgA1	16 mg by mouth once daily x 9 months, then taper over 2 weeks (8 mg once daily) Swallow whole; take at least 1 hour before a meal	None	Peripheral edema, hypertension, muscle spasms, acne, headache, upper respiratory tract infection, face edema, weight gain, dyspepsia, dermatitis, arthralgia, WBC count increased	tarpeyo.com/ savings-and-support
Filspari (sparsentan)	Feb 2023 (Accelerated) Sept 2024 (Full)	**Hit 4/Optimized CKD Therapy:** Dual Endothelin-A & Angiotensin II type 1 receptor antagonist (DEARA)	200 mg by mouth once daily x 14 days, then 400 mg once daily Do not combine with RASi or other ERA	Hepatotoxicity (prescriber, patient, and pharmacy enrollment; ALT, AST, and bilirubin at baseline and Q3 months)	Hyperkalemia, hypotension, peripheral edema, dizziness, anemia, acute kidney injury **Boxed warning:** hepatotoxicity & embryo-fetal toxicity	traveretotalcare.com/ filspari
Fabhalta (iptacopan)	Aug 2024 (Accelerated) Jul 2026 (Full)	**Hit 4:** Complement factor B inhibitor, inhibitor of the alternative complement pathway	200 mg by mouth twice daily Swallow whole; with or without food	Serious encapsulated-bacterial infection (prescriber & pharmacy certification; vaccinate ≥2 weeks before first dose)	Abdominal pain, dizziness, nausea, headache, nasopharyngitis, diarrhea, rash **Boxed warning:** serious infections from encapsulated bacteria	novartis.com/ us-en/patients-and-caregivers/ patient-assistance
Vanrafia (atrasentan)	Apr 2025 (Accelerated)	**Hit 4/Optimized CKD Therapy:** Selective endothelin A receptor antagonist	0.75 mg by mouth once daily To be used in combination with RASi	None	Peripheral edema, anemia, hepatotoxicity, decreased sperm counts **Boxed warning:** Embryo-fetal toxicity	novartis.com/ us-en/patients-and-caregivers/ patient-assistance
Voyxact (sibeprenlimab)	Nov 2025 (Accelerated)	**Hits 1-3:** APRIL-targeting monoclonal antibody that blocks APRIL to modulate B-cells	400 mg subcutaneously every 4 weeks Store in refrigerator. Bring to room temperature 15-30 minutes before injecting	None	Upper respiratory tract infection, injection site erythema	voyxact.com/savings-and-support
Trutakna (atacicept)	Jul 2026 (Accelerated)	**Hits 1-3:** BAFF- and APRIL-targeting fusion protein that blocks both signals to modulate B-cells	150 mg subcutaneously once weekly Store in refrigerator. Bring to room temperature 15-30 minutes before injecting	None	Upper respiratory tract infection, injection site erythema	trutakna.com/ savings-support

Guideline-recommended background therapies (labeled for CKD, not IgAN-specific):

- **RAS inhibitors:** all patients with IgAN should be treated with an optimized maximally tolerated dose of either an ACEi or ARB. Examples: lisinopril, benazepril, enalapril, losartan, valsartan, olmesartan, irbesartan. side effects: hyperkalemia, eGFR dip, cough/angioedema.
- **SGLT2 inhibitors:** patients with IgAN who are at risk of progressive loss of kidney function should be treated with an SGLT2 inhibitor. Examples: Farxiga (dapagliflozin) 10 mg daily, Jardiance (empagliflozin) 10 mg daily. Side effects: genital mycotic infections, urinary tract infections, initial eGFR dip.

*Full FDA approval is made based upon 2-year estimated glomerular filtration rate (eGFR) data in pivotal trials, while accelerated approval is based on 9-month urine protein-creatinine ratio (UPCR) data.

**Therapies are categorized by their predominant mechanisms of action, although many have secondary effects that may also contribute to clinical benefit.

For more information, contact the National Kidney Foundation

Toll-free help line: 855.NKF.CARES or email: nkfcares@kidney.org

Information contained in this NKF educational resource is based on data available at the time of publication. It is intended to help clinicians stay informed about new scientific findings and developments. This resource is not intended to establish a preferred standard of care and should not be interpreted as prescribing an exclusive course of management.

© 2026 National Kidney Foundation, Inc. 742-0568_2609